Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

altaire pharmaceuticals inc. - benoxinate hydrochloride (unii: 0ve4u49k15) (benoxinate - unii:axq0jym303), fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir) - benoxinate hydrochloride 4 mg in 1 ml - altafluor benox (fluorescein sodium and benoxinate hydrochloride ophthalmic solution) 0.25%/0.4% is indicated for ophthalmic procedures requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent. altafluor benox is contraindicated in patients with known hypersensitivity to any component of this product. risk summary   there are no available data on the use of altafluor benox in pregnant women to inform any drug associated risk. adequate animal reproduction studies have not been conducted with fluorescein sodium and/or benoxinate hydrochloride. altafluor benox should be given to a pregnant woman only if clearly needed. risk summary    there are no data on the presence of fluorescein sodium or benoxinate hydrochloride in human milk after ocular administration of altafluor benox, the effects on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for altafluor benox a

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - benralizumab (unii: 71492ge1fx) (benralizumab - unii:71492ge1fx) - benralizumab 30 mg in 1 ml - fasenra is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype [see clinical studies (14)] . limitations of use: fasenra is contraindicated in patients who have known hypersensitivity to benralizumab or any of its excipients [see warnings and precautions (5.1)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to fasenra during pregnancy. healthcare providers can enroll patients or encourage patients to enroll themselves by calling 1-877-311-8972 or visiting mothertobaby.org/fasenra. risk summary the data on pregnancy exposure from the clinical trials are insufficient to inform on drug-associated risk. monoclonal antibodies such as benralizumab are transported across the placenta during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy. in a prenatal and postnatal devel

Iisrael - inglise - Ministry of Health

megapharm ltd - idebenone - film coated tablets - idebenone 150 mg - idebenone - raxone is indicated for the treatment of visual impairment in adolescent and adult patients with leber’s hereditary optic neuropathy (lhon)

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

neurocrine biosciences, inc. - valbenazine tosylate (unii: 5sml1t733b) (valbenazine - unii:54k37p50kh) - valbenazine 40 mg - ingrezza is indicated for the treatment of adults with: - tardive dyskinesia [see clinical studies ( 14.1 )] . - chorea associated with huntington’s disease [see clinical studies ( 14.2 )] . ingrezza is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of ingrezza. rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported [see warnings and precautions ( 5.2 ) and adverse reactions ( 6.2 )]. risk summary the limited available data on ingrezza use in pregnant women are insufficient to inform a drug-associated risk. in animal reproductive studies, no malformations were observed when valbenazine was administered orally to rats and rabbits during the period of organogenesis at doses up to 1.8 or 24 times, respectively, the maximum recommended human dose (mrhd) of 80 mg/day based on mg/m2 body surface area. however, administration of valbenazine to pregnant rats during organogenesis through lactation p

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - benzalkonium chloride - cutaneous spray, solution - 0.20 percent weight/weight - quaternary ammonium compounds

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

cerecor, inc. - benzyl alcohol (unii: lkg8494wbh) (benzyl alcohol - unii:lkg8494wbh) - benzyl alcohol 50 mg in 1 g -       ulesfia®  lotion is indicated for the topical treatment of head lice infestation in patients 6 months of age and older.        ulesfia®  lotion does not have ovocidal activity.       ulesfia®  lotion should be used in the context of an overall lice management program: - wash (in hot water) or dry-clean all recently worn clothing, hats, used bedding, and towels. - wash personal care items such as combs, brushes and hair clips in hot water.   - a fine-tooth comb or special nit comb may be used to remove dead lice and nits.       none.       pregnancy category b       there are no adequate and well-controlled studies with topical benzyl alcohol in pregnant women. reproduction studies conducted in rats and rabbits were negative. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.       no comparisons of animal exposure with human exposure are provided in this labeling due to the low systemic exposure noted in t

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

lachlan pharmaceuticals - benzyl alcohol (unii: lkg8494wbh) (benzyl alcohol - unii:lkg8494wbh) - benzyl alcohol 50 mg in 1 g -       ulesfia®  lotion is indicated for the topical treatment of head lice infestation in patients 6 months of age and older.        ulesfia®  lotion does not have ovocidal activity.       ulesfia®  lotion should be used in the context of an overall lice management program: - wash (in hot water) or dry-clean all recently worn clothing, hats, used bedding, and towels. - wash personal care items such as combs, brushes and hair clips in hot water.   - a fine-tooth comb or special nit comb may be used to remove dead lice and nits.       none.       pregnancy category b       there are no adequate and well-controlled studies with topical benzyl alcohol in pregnant women. reproduction studies conducted in rats and rabbits were negative. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.       no comparisons of animal exposure with human exposure are provided in this labeling due to the low systemic exposure noted in

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

sellars absorbent materials - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - benzalkonium chloride 0.0067275 g - antimicrobial  to sanitize hands without requiring water or a rinse  kills 99.9% of most common germs when using this product  do not use in or near eyes  discontinue use if irritation and redness develop

Kenya - inglise - Pharmacy and Poisons Board

medina remedies limited mombasa road, behind vision plaza. p.o box - benzyl penicillin bp - injection - each vial contains 1mu of benzyl penicillin - beta-lactamantibacterials:

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

ravira limited - benzalkonium chloride solution; cetrimide - cream - 0.01/0.2 percent weight/weight - quaternary ammonium compounds; benzalkonium; cetrimide